Screener
Ligand Pharmaceuticals LGND Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 32.6%+50.9pp | 34.5%+68.5pp | 15.3%+28.8pp | 7%— | -18.3%— | |
| Net margin | 67.9%+108pp | 55.9%+129pp | 46.4%+48.8pp | 19.3%-10.3pp | -40.4%-72.0pp | |
| Returns | ||||||
| Return on equity | 22%+31.4pp | 17.1%+33.7pp | 13.5%+14.0pp | 5.4%-0.6pp | -9.5%-15.3pp | |
| Return on invested capital | 8.5%+12.9pp | 9.6%+17.7pp | 4%+7.1pp | 2.2%+1.6pp | -4.5%-5.1pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Liquidity | ||||||
| Current ratio | 31.2×+25.7× | 21.3×+16.0× | 22.2×+13.3× | 24.7×+12.2× | 5.5×-11.4× | |
| Leverage | ||||||
| Debt-to-equity | 1.2×+1.2× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | 1×+96.7× | -0.9×— | -2.3×+2.9× | -2.6×-1.2× | -95.7×-95.4× | |
| Per Share | ||||||
| Book value per share | $44.31+6.7% | $50.16+21.0% | $50.12+10.4% | $46.06+0.9% | $41.52-3.4% | |
| Valuation | ||||||
| Market capitalization | $6.02B+119% | $3.98B+96.7% | $3.72B+83.8% | $3.45B+88.9% | $2.28B+50.7% | |
| Price / earnings | 30.5×— | 25.9×— | 29.9×— | 71.1×+30.7× | —— | |
| Price / sales | 20.7×+6.1× | 14.5×+3.3× | 13.9×+1.8× | 13.7×+1.7× | 12.2×+0.8× | |
| Price / book | 6.2×+2.9× | 4×+1.4× | 3.7×+1.2× | 3.6×+1.5× | 2.8×+0.8× | |
| EV / EBITDA | 48.1×-4,103× | 30.3×— | 47.5×-108× | 64.2×+19.6× | 3,429.7×+3,392× |
FAQ
- What are Ligand Pharmaceuticals's profit margins?
- Ligand Pharmaceuticals (LGND) runs a 91.9% gross margin and a 32.6% operating margin, with a 67.9% net margin.
- Where do Ligand Pharmaceuticals's ratios come from?
- Every ratio is computed from Ligand Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
